A vaccine candidate from China has finished its phase-1 trial on humans. As per reports, the trials show the vaccine is ’safe’ and ’induces rapid immune response’. The research injected the potential vaccine into 108 volunteers. Antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28. A phase-2 clinical trial has begun with 508 volunteers.